iScience (Mar 2022)

Chorioallantoic membrane tumor models highlight the effects of cisplatin compounds in oral carcinoma treatment

  • Patrizia Sarogni,
  • Ana Katrina Mapanao,
  • Alessandra Gonnelli,
  • Maria Laura Ermini,
  • Sabrina Marchetti,
  • Claudia Kusmic,
  • Fabiola Paiar,
  • Valerio Voliani

Journal volume & issue
Vol. 25, no. 3
p. 103980


Read online

Summary: The European Society for Medical Oncology (ESMO) suggests the use of chemotherapy as neoadjuvant, adjuvant, and concomitant to surgery and radiotherapy for the treatment of oral carcinoma by depending on the cancer stage. The usual drug of choice belongs to the platinum compounds. In this context, the evaluation of the cancer behavior associated with the administration of standard or emerging cisplatin compounds supports the establishment of optimal cancer management. Here, we have assessed and compared the performance of cisplatin alone and contained in biodegradable nanocapsules on standardized chorioallantoic membrane (CAM) tumor models. The vascularized environment and optimized grafting procedure allowed the establishment of solid tumors. The treatments showed antitumor and anti-angiogenic activities together with deregulation of pivotal genes responsible of treatment resistance and tumor aggressiveness. This study further supports the significance of CAM tumor models in oncological research for the comprehension of the molecular mechanisms involved in tumor treatment response.